anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intraoperative remifentanil administration has been linked to increased postoperative pain sensitivity. Recent studies have identified the involvement of euchromatic histone-lysine N-methyltransferase 2 (Ehmt2/G9a) in neuropathic pain associated with the transcriptional silencing of many potassium ion channel genes. This study investigates whether G9a regulates the potassium sodium-activated channel subfamily T member 1 (Slo2.2) in remifentanil-induced post-incisional hyperalgesia (RIH) in rodents. We performed remifentanil infusion (1 μg·kg-1·min-1 for 60 min) followed by plantar incision to induce RIH in rodents. Our results showed that RIH was accompanied by increased G9a and H3K9me2 production and decreased Slo2.2 expression 48 h postoperatively. Deletion of G9a rescued Slo2.2 expression in DRG and reduced RIH intensity. Slo2.2 overexpression also reversed this hyperalgesia phenotype. G9a overexpression decreased Slo2.2-mediated leak current and increased excitability in the small-diameter DRG neurons and laminal II small-diameter neurons in the spinal dorsal horn, which was implicated in peripheral and central sensitization. These results suggest that G9a contributes to the development of RIH by epigenetically silencing Slo2.2 in DRG neurons, leading to decreased central sensitization in the spinal cord. The findings may have implications for the development of novel therapeutic targets for the treatment of postoperative pain.
Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
FIELD: medicine. SUBSTANCE: invention relates to development of analogs of protein hormones. Invention proposes to use antrarelix, ganirelix, antide or A-75998 slight salts and embonic acid salt also as analogs of releasing hormone-luteonizing hormone. Invention relates to also pharmaceutical composition based on each the above indicated salt. EFFECT: broadened arsenal of agent used for correction of hormonal regulation. 7 cl, 4 dwg
The experimental group received a 35-minute training course for 2 weeks, 3 times a week, each time during the hospitalization. A total of 4 assessments were performed: baseline (pre-intervention), after third-time intervention, post-intervention, and one week after the intervention.
PURPOSE:To obtain a poultice low in the manifestation rate of side effects such as flare, an itch, a rash or eruption and having high anti-inflammatory/ analgestic effect, in a poultice wherein a support layer and a medicinal component-containing layer containing a medicinal component are laminated, by providing a layer containing a far infrared ray emitting substance. CONSTITUTION:A poultice consists of a layer 1 containing a far infrared ray emitting substance 3 and a layer 2 containing a medicinal component. The layer 1 containing the far infrared ray emitting substance 3 is formed by compounding the far infrared ray emitting substance with a thermoplastic resin low in the absorption of far infrared rays and molding the resulting mixture into a support. The compounding ratio of the far infrared ray emitting substance in the mixture is usually 3wt.% or more, pref., 5-30wt.%. The medicinal component layer 2 is formed by applying a mixture of a binder and the medicinal component to the layer 1 containing the far infrared ray emitting substance uniformly so as to usually adjust the medicinal component to 0.05g/m<2> or more. As the far infrared ray emitting substance, silica-alumina ceramics containing 35-100wt.% of SiO2 and 0-5wt.% of components composed of Fe2O3, CaO, MgO, NiO and H2O.
Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
Myocarditis is an inflammation of the heart muscle often associated with viral infections and can lead to dilated cardiomyopathy. Interferon-induced transmembrane protein 3 (IFITM3) is a small endosomal membrane protein with anti-viral activity against multiple viruses and is also implicated in non-infectious diseases such as cancer and Alzheimer's Disease. Since the IFITM3 proteins are expressed both in T cells and in cardiomyocytes, it is reasonable to hypothesize that these molecules could affect myocarditis either through their effect on the autoimmune response or through direct modulation of cardiomyocyte damage. The aim of this study was to investigate the role of IFITM3 in experimental autoimmune myocarditis (EAM)-mediated myocardial injury. Immunization of rats with cardiac myosin results in substantial cardiac inflammation and is associated with increased expression of IFITM3 after 21 days. In vivo IFITM3 shRNA knockdown using the lentivirus transfection method reduced cardiac injury while restoring IFITM3 expression reversed the protective effect of IFITM3 RNA interference. To determine the direct impact of IFITM3, the rat ventricular cell line, H9c2, was treated with palmitic acid which causes apoptosis in these cells. Suppressing IFITM3 expression protects H9c2 cells while overexpressing IFITM3 enhances cell injury. JAK inhibitors reduced IFITM3-mediated myocardial cell injury. In conclusion, IFITM3 may mediate myocardial injury in EAM rats and palmitic acid-induced damage to H9c2 cells through the JAK2/STAT3 pathway.
PURPOSE:To obtain a hair-dyeing composition of high safety and stability, showing good applicability such as high spreadability and coatability despite of no sagging of the hair dye during dyeing treatment and without dyeing speck, comprising a specific saccharide derivative and an oxidation coloring agent. CONSTITUTION:This oxidation hair-dyeing agent composition comprises the combination of a saccharide derivative of formula I (A is a residue after exclusion of (n)XOH groups from the saccharide; (n) is >=1) with an oxidation coloring agent. As the saccharide derivative, that of formula I to be a branched aliphatic glycoside of formula II (A is a residue after exclusion of hemiacetal hydroxy groups from the saccharide, or a saccharide branched aliphatic ether of formula III (A is a residue after exclusion of (n)Xnon-hemiacetal OH groups from the saccharide) is particularly preferred. Particularly, iso-stearly maltoside and maltitol isostrearly ether are preferred. It is preferred that an oxidizing agent is added to these compositions. Particularly, a composition obtained by mixing the first agent containing the saccharide derivative and an oxidation coloring agent simultaneously with the second agent containing the oxidizing agent is preferred.
BACKGROUND: The accurate identification of microvascular invasion (MVI) in patients with hepatocellular carcinoma (HCC) is of great clinical importance.
PURPOSE: To develop a radiomics nomogram based on susceptibility-weighted imaging (SWI) and T2-weighted imaging (T2WI) for predicting MVI in early-stage (Barcelona Clinic Liver Cancer stages 0 and A) HCC patients.
MATERIALS AND METHODS: A prospective cohort of 189 participants with HCC was included for model training and testing, and an additional 34 participants were enrolled for external validation. ITK-SNAP was used to manually segment the tumour, and PyRadiomics was used to extract radiomic features from the SWI and T2W images. Variance filtering, student's t test, least absolute shrinkage and selection operator regression and random forest (RF) were applied to select meaningful features. Four machine learning classifiers, including K-nearest neighbour, RF, logistic regression and support vector machine-based models, were established. Independent clinical and radiological risk factors were also determined to establish a clinical model. The best radiomics and clinical models were further evaluated in the validation set. In addition, a nomogram was constructed from the radiomic model and independent clinical factors. Diagnostic efficacy was evaluated by receiver operating characteristic curve analysis with fivefold cross-validation.
RESULTS: AFP levels greater than 400 ng/mL [odds ratio (OR) 2.50; 95% confidence interval (CI) 1.239-5.047], tumour diameter greater than 5 cm (OR 2.39; 95% CI 1.178-4.839), and absence of pseudocapsule (OR 2.053; 95% CI 1.007-4.202) were found to be independent risk factors for MVI. The areas under the curve (AUCs) of the best radiomic model were 1.000 and 0.882 in the training and testing cohorts, respectively, while those of the clinical model were 0.688 and 0.6691. In the validation set, the radiomic model achieved better diagnostic performance (AUC = 0.888) than the clinical model (AUC = 0.602). The combination of clinical factors and the radiomic model yielded a nomogram with the best diagnostic performance (AUC = 0.948).
CONCLUSION: SWI and T2WI-derived radiomic features are valuable for noninvasively and accurately identifying MVI in early-stage HCC. Furthermore, the integration of radiomics and clinical factors yielded a predictive nomogram with satisfactory diagnostic performance and potential clinical benefits.
A powder composition for forming a cosmetic nail coating comprises an acrylic polymer or copolymer, and about 0.01 wt % to about 1.0 wt % of tertiary phosphine. The tertiary phosphine comprises three aryl groups, alkyl groups, or combination thereof. An example of the tertiary phosphine is a triaryl phosphine that may be substituted with 1 to 3 alkyl groups. A method of forming a cosmetic nail coating comprises the steps of (i) applying to a nail a cyanoacrylate adhesive; and (ii) contacting the nail with the powder composition. No application of an activator is necessary. The advantages of such a method include that fewer steps are needed in order to obtain a nail coating, the increased speed that the system cures, and a safer toxicological profile of the ingredients.
A sleep monitoring device is provided. A motion detection circuit detects a human body motion to generate a detection signal. A processing circuit retrieves and executes computer executable commands from a storage circuit to execute a sleep monitoring method including steps outlined below. The detection signal is received from the motion detection circuit. A total time length that an activity strength of the detection signal is larger than a predetermined value within a basic unit time is accumulated as an activity amount. A statistics is performed on the activity amount of each of the basic unit time for a plurality of different time ranges, to generate a total activity amount. Whether the total activity amount exceeds one of a plurality of activity threshold values is determined to generate an activity scale determination result. A sleep status is determined according to the activity scale determination result.
Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol.
NEW MATERIAL:The linear oligoester of formula I or cyclic oligoester of formula II. USE:It has metallic ion capturing activity. It exhibits similar activity as natural ionophores, and has antibacterial activity. The compound can be used as pharmaceuticals or agricultural chemicals, and also as an ion sensor taking advantage of the cationic selectivity. PREPARATION:A cyclic oligoester of 5-hydroxymethyl-2-furancarboxylic acid is prepared beforehand. The hydrogenation of the furan ring and the hydrogenative decomposition of a part of the ester bond are carried out to obtain a linear oligoester and a cyclic oligoester at the same time, which are separated from each other by column separation technique. The above reaction is carried out using rhodium/activated carbon catalyst and a hydrogenation solvent such as tetrahydrofuran, ethyl alcohol, ethyl acetate, etc. The amount of the rhodium metal of the rhodium/activated carbon is at least 5-10mol% based on the monomer unit of the cyclic oligoester of 5-hydroxymethyl-2-furancarboxylic acid.
This invention relates to the derivatives of an oxygen deficiency contrast medium HL91-NI structure. It utilizes organic synthesis method to prepare two derivatives of HL91 (4, 9-diaza-3, 3, 10, 10-tetramethyldodecan-2, 11-dione dioxime) structure. One HL91 structure derivative is HL91-NI, it becomes 2-nitroimidazole functional base. Wherein, the HL91 structure is prepared by the organic synthesis method. The other derivative of HL91 structure is HL91-ET, it revises the HL91 chemical constitution, and lengthens the side carbon chain preparation. By means of the preparation method for HL91 structure derivatives, it enhances the specificity of medicine, and reduces the polarity of medicine. Eventually, it promotes the dose of medicine entering into the cell. Therefore, it improves the sensitivity of medicine.
FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention provides a pharmaceutical composition for preventing or treating cardiovascular disorders. Pharmaceutical composition contains losartan or its pharmaceutically acceptable salt, amlodipine or its pharmaceutically acceptable salt, a disintegrating agent in amount of 3 - 10 wt. % of the total weight of the composition and a coating agent. Disintegrant is selected from a group consisting of sodium glycolate, croscarmellose sodium and crospovidone. Coating agent contains hypromellose, having viscosity of 10 to 30 mPa·s and contained in amount of 1 to 10 wt. % based on the total weight of the composition. Weight ratio of disintegrating agent and coating agent in composition ranges from 1.5:1 to 4.0:1. Composition can be prepared in the form of a coated tablet, which shows an increase in thickness by 3 % or less when subjected to accelerated test conditions for 5 hours 40 °C and 75 % relative humidity and demonstrates weight increase by 5 % or less when exposed to accelerated test conditions for 5 hours 40 °C and 75 % relative humidity.EFFECT: tablet of losartan and amlodipine with hypromellose coating according to the invention is characterized by stability during storage and provides inhibition of accompanying admixtures.9 cl, 4 dwg, 7 tbl, 3 ex
This was a multicenter, open-label, dose-escalation, sequential groups Phase 1b clinical study in subjects with R/R multiple myeloma. The study utilized a "3+3" design. Three subjects were enrolled at each dose, starting with the initial dose of 4 mg/kg. If there were no DLTs, escalation to the next cohort took place. If there was 1 DLT, then the cohort was to be expanded to 6. If there were no further DLTs, then escalation to the next dose took place. If there were 2 DLTs in the initial 3 subjects, or 2 in the expanded cohort of 6 subjects, then the maximally tolerated dose (MTD) had been exceeded and dose escalation stopped. The dose prior to the dose where DLT was observed was then the RP2D. To allow safety assessment, the dosing of subjects within each dose level was staggered, with at least 24 hours between each subject.
Two-year carcinogenicity studies in mice and rats at subcutaneous doses of 10, 30, or 100 mcg/kg/day did not show any evidence of carcinogenic potential. However, at 100 mcg/kg/day, male rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was not reached in the mouse study. The high dose (100 mcg/kg) corresponds to exposure levels over 400 times the human exposure at the maximum recommended human ocular dose (MRHOD) of 0.04 mcg/kg, based on plasma active drug levels.

Travoprost was not mutagenic in the Ames test, mouse micronucleus test or rat chromosome aberration assay. A slight increase in the mutant frequency was observed in one of two mouse lymphoma assays in the presence of rat S-9 activation enzymes.

Travoprost did not affect mating or fertility indices in male or female rats at subcutaneous doses up to 10 mcg/kg/day [250 times the maximum recommended human ocular dose of 0.04 mcg/kg/day on a mcg/kg basis (MRHOD)]. At 10 mcg/kg/day, the mean number of corpora lutea was reduced, and the post-implantation losses were increased. These effects were not observed at 3 mcg/kg/day (75 times the MRHOD).
BACKGROUND AND PURPOSE: Multiple system atrophy (MSA) is a neurodegenerative disease with characteristic motor and autonomic symptoms. Impaired brain serotonergic innervation can be associated with various clinical indices of MSA; however, the relationship between clinical symptoms and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5-HIAA), a main serotonin metabolite, has not been fully elucidated.
METHODS: To compare CSF 5-HIAA levels between patients with MSA and healthy controls, we included 33 controls and 69 MSA patients with either predominant parkinsonian or cerebellar ataxia subtypes. CSF 5-HIAA levels were measured using high-performance liquid chromatography. Additionally, we investigated correlations between CSF 5-HIAA and various clinical indices in 34 MSA patients.
RESULTS: CSF 5-HIAA levels were significantly lower in MSA patients than in controls (p < 0.0001). Probable MSA patients had lower CSF 5-HIAA levels than possible MSA patients (p < 0.001). In MSA patients, CSF 5-HIAA levels were inversely correlated with scores in Parts 1, 2, and 4 of the Unified Multiple System Atrophy Rating Scale, and with systolic and diastolic blood pressure in Part 3. Structural equation modeling revealed significant paths between serotonin and clinical symptoms, and significance was highest for activities of daily living, walking, and body sway.
CONCLUSIONS: Serotonin dysfunction, as assessed by CSF 5-HIAA levels, may implicate greater MSA severity.
Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
Skin treatment compositions and methods provide a superficial depth skin peel and exfoliation utilizing a combination of four acids, a carrier gel, colorant(s), and a topical oxygen delivery system. The combination of acids, oxygen delivery, gel formulation and colorant(s) aid in the efficacy of the formulations to result in beneficial skin treatment compositions by creating an effective superficial peel without the use of BHA's and only using AHA's having a molecular weight greater than 100. The AHA's used in the present invention are intended to predominately impact the stratum corneum, the outermost layer of skin. The AHA's utilized in the present invention reduce corneocyte adhesion by impacting the ionic bonds in a manner that reduces the cohesion forces. The corneocytes are then more easily shed and replaced by the newer, bright layers underneath. This can give the skin a smoother and less scaly appearance.
PURPOSE:To obtain HBs antibody-producing cell having high antibody productivity from the transformed subculture cell, by heating an HBs antigen in the presence of a protein denaturating agent, and using the denaturated antigen as an immunogen. CONSTITUTION:An HBs antigen is recovered from the blood positive to human HBs antigen by conventional plasma fractionation method (e.g. ammonium sulfate precipitation method). The recovered and purified HBs antigen is heat- treated in the presence of a protein denaturating agent such as urea or guanidine (preferably 6-8mol) at 6.5-7.5pH and 60-120 deg.C. A solution of HBs antigen adjusted to a proper concentration and filtered to remove bacteria, is used as an immunogen and made to contact with human B lymphocyte cells, which is stimulated its antibody-producing activity by this process. The cells are sensitized with lymphotropic virus (e.g. EB virus) to effect the transformation to a productive cell. Cells producing HBs antibody is selected from the above productive cells, and concentrated and proliferated to produce the monoclonal HBs antibody continuously.
Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
PURPOSE: The use of an antiallergic material derived from a hot water extract of Asterias amurensis is provided. The extract remarkably reduces the contraction as an allergic response of an allergic asthma model in a test tube and the effect thereof is increased as an applied concentration is increased. CONSTITUTION: Asterias amurensis is extracted in distilled water for 6hr, the extract thereof is freeze-dried and administrated into a test animal. A passive cutaneous anaphylaxis(PCA) reaction of a rat corresponding to a general allergic reaction is reduced. Thus, the Asterias amurensis extract exerts a significant inhibiting effect on the PCA reaction. In the measurement of antiallergic activity in Guinea pig as an in vitro model for allergic asthma, the extract concentrated 0.25mg/ml or more reduces the contraction as an allergic response in a test tube.
Bevacizumab combined with CapeOx(Oxaliplatin+Capecitabine) were used for 4-8 cycles, each cycle is 3 weeks. After 8 cycles, the regimen is changed to Bevacizumab combined with Capecitabine.
Myelosuppression occurs in 25% to 30% of patients treated with cisplatin. The nadirs in circulating platelets and leukocytes occur between days 18 to 23 (range 7.5 to 45) with most patients recovering by day 39 (range 13 to 62). Leukopenia and thrombocytopenia are more pronounced at higher doses (>50 mg/m 2). Anemia (decrease of 2 g hemoglobin/100 mL) occurs at approximately the same frequency and with the same timing as leukopenia and thrombocytopenia. Fever and infection have also been reported in patients with neutropenia. Potential fatalities due to infection (secondary to myelosuppression) have been reported. Elderly patients may be more susceptible to myelosuppression (see PRECAUTIONS , Geriatric Use). 

In addition to anemia secondary to myelosuppression, a Coombs’ positive hemolytic anemia has been reported. In the presence of cisplatin hemolytic anemia, a further course of treatment may be accompanied by increased hemolysis and this risk should be weighed by the treating physician.

The development of acute leukemia coincident with the use of cisplatin has been reported. In these reports, cisplatin was generally given in combination with other leukemogenic agents.